Taysha Gene Therapies (TSHA) Other Non-Current Liabilities (2020 - 2026)

Taysha Gene Therapies has reported Other Non-Current Liabilities for 7 years, with the latest figure at $1.6 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 31.83% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 31.83% YoY) and the FY2025 annual result came in at $1.6 million, up 18.56% from the prior year.
• Other Non-Current Liabilities grew to $1.6 million in Q1 2026 per TSHA's latest filing, from $1.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $4.1 million in Q4 2022 and troughed at $1.2 million in Q1 2025.
• A 5-year average of $2.4 million and a median of $1.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities jumped 354.9% in 2022, then sank 64.81% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $4.1 million in 2022, then sank by 61.82% to $1.6 million in 2023, then decreased by 16.99% to $1.3 million in 2024, then climbed by 18.56% to $1.6 million in 2025, then advanced by 1.93% to $1.6 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.6 million, $1.6 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.